- Home
- IMMP vs ATYR Comparison
IMMP vs ATYR Comparison
Compare IMMP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- ATYR
- Stock Information
- Founded
- IMMP 1987
- ATYR 2005
- Country
- IMMP Australia
- ATYR United States
- Employees
- IMMP N/A
- ATYR N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMP Health Care
- ATYR Health Care
- Exchange
- IMMP Nasdaq
- ATYR Nasdaq
- Market Cap
- IMMP 251.8M
- ATYR 535.0M
- IPO Year
- IMMP N/A
- ATYR 2015
- Fundamental
- Price
- IMMP $1.69
- ATYR $1.08
- Analyst Decision
- IMMP Buy
- ATYR Buy
- Analyst Count
- IMMP 1
- ATYR 6
- Target Price
- IMMP $7.00
- ATYR $8.88
- AVG Volume (30 Days)
- IMMP 87.2K
- ATYR 14.2M
- Earning Date
- IMMP 10-21-2025
- ATYR 11-06-2025
- Dividend Yield
- IMMP N/A
- ATYR N/A
- EPS Growth
- IMMP N/A
- ATYR N/A
- EPS
- IMMP N/A
- ATYR N/A
- Revenue
- IMMP $3,306,742.00
- ATYR N/A
- Revenue This Year
- IMMP N/A
- ATYR $420.85
- Revenue Next Year
- IMMP $725.37
- ATYR $1,919.44
- P/E Ratio
- IMMP N/A
- ATYR N/A
- Revenue Growth
- IMMP 31.28
- ATYR N/A
- 52 Week Low
- IMMP $1.32
- ATYR $1.00
- 52 Week High
- IMMP $2.71
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- IMMP 50.87
- ATYR 22.44
- Support Level
- IMMP $1.60
- ATYR $1.00
- Resistance Level
- IMMP $1.76
- ATYR $6.50
- Average True Range (ATR)
- IMMP 0.06
- ATYR 0.46
- MACD
- IMMP 0.01
- ATYR -0.42
- Stochastic Oscillator
- IMMP 58.82
- ATYR 1.45
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.